JP2009153527A5 - - Google Patents

Download PDF

Info

Publication number
JP2009153527A5
JP2009153527A5 JP2009092502A JP2009092502A JP2009153527A5 JP 2009153527 A5 JP2009153527 A5 JP 2009153527A5 JP 2009092502 A JP2009092502 A JP 2009092502A JP 2009092502 A JP2009092502 A JP 2009092502A JP 2009153527 A5 JP2009153527 A5 JP 2009153527A5
Authority
JP
Japan
Prior art keywords
antibody
hybrid
hybrid antibody
antibody fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009092502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009153527A (ja
JP5054058B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009153527A publication Critical patent/JP2009153527A/ja
Publication of JP2009153527A5 publication Critical patent/JP2009153527A5/ja
Application granted granted Critical
Publication of JP5054058B2 publication Critical patent/JP5054058B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2009092502A 2001-12-03 2009-04-06 ハイブリッド抗体 Expired - Fee Related JP5054058B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33659101P 2001-12-03 2001-12-03
US60/336,591 2001-12-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003549500A Division JP4723810B2 (ja) 2001-12-03 2002-12-03 ハイブリッド抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012056050A Division JP2012144551A (ja) 2001-12-03 2012-03-13 ハイブリッド抗体

Publications (3)

Publication Number Publication Date
JP2009153527A JP2009153527A (ja) 2009-07-16
JP2009153527A5 true JP2009153527A5 (https=) 2010-11-11
JP5054058B2 JP5054058B2 (ja) 2012-10-24

Family

ID=23316785

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003549500A Expired - Fee Related JP4723810B2 (ja) 2001-12-03 2002-12-03 ハイブリッド抗体
JP2009092502A Expired - Fee Related JP5054058B2 (ja) 2001-12-03 2009-04-06 ハイブリッド抗体
JP2012056050A Withdrawn JP2012144551A (ja) 2001-12-03 2012-03-13 ハイブリッド抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003549500A Expired - Fee Related JP4723810B2 (ja) 2001-12-03 2002-12-03 ハイブリッド抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012056050A Withdrawn JP2012144551A (ja) 2001-12-03 2012-03-13 ハイブリッド抗体

Country Status (12)

Country Link
US (1) US7399594B2 (https=)
EP (2) EP2298817A1 (https=)
JP (3) JP4723810B2 (https=)
AT (1) ATE550352T1 (https=)
AU (1) AU2002359568B2 (https=)
CA (1) CA2468744C (https=)
CY (1) CY1112843T1 (https=)
DK (1) DK1461428T3 (https=)
ES (1) ES2384100T3 (https=)
PT (1) PT1461428E (https=)
SI (1) SI1461428T1 (https=)
WO (1) WO2003048321A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7393648B2 (en) * 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP1521776A2 (en) * 2002-07-04 2005-04-13 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
MXPA06000258A (es) * 2003-07-15 2006-07-03 Cambridge Antibody Tech Moleculas de anticuerpo humano para interleucina-13.
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
CA2545756A1 (en) * 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
DE10353175A1 (de) * 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005058251A2 (en) * 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
CA2562034A1 (en) * 2004-03-31 2005-10-20 Jin Lu Method and apparatus for analyzing and generating human antibody amino acid and nucleic acid sequences
US20060263787A1 (en) * 2004-05-10 2006-11-23 Evans Glen A Immunoglobulin-like variable chain binding polypeptides and methods of use
GB0414886D0 (en) * 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP1907001B1 (en) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
CA2655903A1 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
ME03057B (me) 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
KR101759457B1 (ko) * 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173
US20110052565A1 (en) * 2007-12-21 2011-03-03 National Research Council Of Canada Non-aggregating human vh domains
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2356154A4 (en) * 2008-11-06 2012-12-19 Alexion Pharma Inc DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
EP2411050A4 (en) * 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
EP2542258A4 (en) * 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
EP3323830B1 (en) * 2010-06-19 2023-08-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
HRP20182129T1 (hr) * 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
RU2680267C2 (ru) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер Высокоаффинные антитела к gd2
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) * 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
DE69333115D1 (de) 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
ATE267610T1 (de) * 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
US5908925A (en) * 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
WO2003025019A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules

Similar Documents

Publication Publication Date Title
JP2009153527A5 (https=)
JP2020535799A5 (https=)
JP2024109678A5 (https=)
JP2023113686A (ja) pH依存的抗体の調製方法
KR102290949B1 (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
RU2010102064A (ru) Способ конструирования, основанный на определении последовательностей, способ оптимизации одноцепочечных антител
WO2012163520A4 (en) Dual targeting
JP2015517309A5 (https=)
JP2008520586A5 (https=)
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
US12441803B2 (en) Engineered CD25 polypeptides and uses thereof
IL261673A (en) Protein-like binding proteins with a double variable region have a cross-linking region direction
JP2017052784A5 (https=)
JP2020504101A5 (https=)
JP2019201643A5 (https=)
JP2014500725A5 (https=)
JP2012527881A5 (https=)
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
JP2021500916A5 (https=)
JP2011527899A5 (https=)
NZ581418A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
JP2015028021A5 (https=)
WO2005118635A3 (en) Anti-cd3 antibodies and methods of use thereof
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2006052591A3 (en) Anti-properdin antibodies, and methods for making and using same